Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Myeloma, Newly Diagnosed”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT04196491
What this trial is testing

Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Celgene 13
Testing effectiveness (Phase 2)Study completedNCT01264315
What this trial is testing

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 53
Testing effectiveness (Phase 2)Active Not RecruitingNCT04140162
What this trial is testing

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Who this might be right for
Multiple Myeloma
University of Michigan Rogel Cancer Center 57
Testing effectiveness (Phase 2)Study completedNCT00691704
What this trial is testing

Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

Who this might be right for
Multiple Myeloma
Cristina Gasparetto 18
Post-approval studies (Phase 4)UnknownNCT03908138
What this trial is testing

RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

Who this might be right for
Hematologic NeoplasmsMultiple MyelomaEfficacy+1 more
Shandong Provincial Hospital 120
Large-scale testing (Phase 3)Active Not RecruitingNCT03948035
What this trial is testing

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Who this might be right for
Newly Diagnosed Multiple Myeloma
Wuerzburg University Hospital 576
Large-scale testing (Phase 3)Looking for participantsNCT07665450
What this trial is testing

Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT05695508
What this trial is testing

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Who this might be right for
Multiple Myeloma
University of Heidelberg Medical Center 160
Testing effectiveness (Phase 2)Active Not RecruitingNCT06577025
What this trial is testing

Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT04717700
What this trial is testing

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Who this might be right for
Multiple Myeloma
Ida Bruun Kristensen 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT05850286
What this trial is testing

VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 20
Large-scale testing (Phase 3)Study completedNCT00633542
What this trial is testing

Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM)

Who this might be right for
Multiple Myeloma
Università Politecnica delle Marche 103
Large-scale testing (Phase 3)Study completedNCT01208766
What this trial is testing

Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stichting Hemato-Oncologie voor Volwassenen Nederland 1,503
Large-scale testing (Phase 3)Active Not RecruitingNCT05257083
What this trial is testing

Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stichting European Myeloma Network 759
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06963866
What this trial is testing

Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Xuzhou Medical University 60
Not applicableStudy completedNCT07206810
What this trial is testing

The Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients

Who this might be right for
Myeloma
The First Affiliated Hospital of Soochow University 419
Testing effectiveness (Phase 2)Active Not RecruitingNCT03290950
What this trial is testing

Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 69
Testing effectiveness (Phase 2)Looking for participantsNCT07106710
What this trial is testing

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Ultra-High-Risk Multiple Myeloma

Who this might be right for
Multiple Myeloma, Newly Diagnosed
Institute of Hematology & Blood Diseases Hospital, China 30
Not applicableNot Yet RecruitingNCT07070960
What this trial is testing

Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible

Who this might be right for
Multiple MyelomaNewly Diagnosed
Xuzhou Medical University 35
Early research (Phase 1)Study completedNCT03984097
What this trial is testing

Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma
Takeda 50
Next Page